Amino Acid Supplement Boosts mRNA Delivery and Gene Editing Efficiency
Similar Articles
Engineered Nanoparticles Show Promise in Restoring Brain Waste Removal in Alzheimer's Mouse Model
Arginine Shows Promise in Reducing Alzheimer's Plaques in Animal Studies
Researchers Identify Brain Cell Process That Removes Alzheimer's Plaques in Mice
UC Davis Researchers Develop Light-Driven Method to Create Non-Hallucinogenic Psychedelic-Like Compounds
Injectable Biomaterial Shows Promise for Repairing Heart Attack Damage
Researchers have discovered that adding a specific amino acid mixture to lipid nanoparticles (LNPs) dramatically improves their ability to deliver therapeutic mRNA and CRISPR gene-editing tools. This enhancement increased mRNA delivery by up to 20-fold and raised CRISPR editing efficiency from about 25% to nearly 90% in animal models. The finding could significantly advance treatments for cancer, genetic diseases, and acute conditions.
Facts First
- Adding methionine, arginine, and serine to LNPs boosted mRNA delivery up to 20-fold.
- CRISPR gene editing efficiency rose from approximately 25% to nearly 90% after a single dose.
- In a mouse model of liver failure, survival with growth hormone mRNA therapy jumped from 33% to 100% when the amino acid supplement was used.
- Protein production from delivered mRNA increased 5- to 20-fold across multiple cell types and delivery methods.
- The supplement worked in intramuscular, intratracheal, and intravenous delivery.
What Happened
A research team at Biohub published a study in Science Translational Medicine finding that adding three amino acids—methionine, arginine, and serine—to lipid nanoparticles (LNPs) greatly enhances their performance. LNPs are the delivery vehicles used for COVID-19 mRNA vaccines and are being developed for delivering therapeutic mRNA for cancer and inflammatory diseases, as well as CRISPR systems for fixing genetic mutations. In laboratory experiments and living animals, this targeted supplement increased protein production from delivered mRNA between 5- and 20-fold across multiple cell types.
Why this Matters to You
This discovery may lead to more effective treatments for a range of serious conditions. For patients with genetic disorders, a single dose of a CRISPR-based therapy could become far more reliable. For those facing acute medical crises, like liver failure, the enhanced delivery could make life-saving mRNA treatments dramatically more successful. The research also addresses a key challenge: standard lab conditions don't accurately mimic the human body. This supplement appears to overcome the barrier of decreased LNP uptake in human blood plasma, which could make future therapies developed in labs work better when they reach patients.
What's Next
The researchers' amino acid mixture worked across multiple delivery methods—intramuscular, intratracheal, and intravenous—suggesting it could be broadly applicable. Further development and testing will be needed to translate these laboratory and animal model results into safe and effective human therapies. The significant improvements in gene editing efficiency could accelerate the development of mRNA and CRISPR-based treatments for cancer, inflammatory diseases, and genetic conditions.